Current translational and basic prostate\ud
cancer research is limited by the number of\ud
cell lines that truly reflect the spectrum of\ud
disease progression, with most commonly\ud
used cell lines being derived from metastatic\ud
lesions. There are essentially no prostate\ud
cancer cell lines derived from primary\ud
tumours or localised disease in wide use